Cloning,expression and purification of rift valley fever virus recombinant G2 protein in bacterial system

Abstract EN

-Background : Rift Valley Fever Virus RVFV is a major health problem in Egypt and the African Sahara, transmitted by the bite of mosquitoes Two commercially types of available vaccines are; the dead and attenuated vaccine.

They are effective but carry a degree of problems in efficiency, uniformity and possibility of abortion of cattle.

It was inevitable tendency to search for a safe and effective design of a protein-unitary vaccine by using genetic engineering.

Of the three parts of a single internal DNA negative strand genome, the medium non-structural part code for a polyprotein is the precursor to the glycoproteins G1 and G2 and two nonstructural proteins.

Aim : This research aimed to produce recombinant protein of the gene G2 (rG2) of RVFV and to study its immunogenicity to apply it as a vaccine.

Materials: For this purpose, virus of Menya (m /s / 258) strain was used to measure the strength and then was increased by seeding in chicken embryo cells.

Part of glycoprotein G2 was successfully excised from whole RVFV genome to form recombinant G2 (rG2).

rG2 was cloned, ligated for expression vector and purified.

Results and Conclusion ; The definition of rG2 protein was at » 18-19 Kilodalton.

The produced RVFV recombinant protein in infected mice has high vaccine effectiveness and interacted with the anti-serum of mice with output reductions event at 1: 1024.

Recombinant G2 protein protected 65 % of mice from lethal live RVFV challenge